Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Product | Forecast to 2029
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Is The Cancer Immunotherapy Drug Discovery Outsourcing Market Expected To Grow In Terms Of Size?
The market size for outsourcing the discovery of cancer immunotherapy drugs has seen significant expansion in the last few years. It is projected to rise from $1.5 billion in 2024 to $1.66 billion in 2025, marking a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this growth during the historical period include a rise in adverse drug reaction instances, an escalated demand for extensive genomic testing, a worldwide increase in cancer cases, an escalating need for targeted treatment, and an increase in clinical trials.
The market for outsourcing the discovery of cancer immunotherapy drugs is predicted to experience a notable expansion in the next several years. The market size is forecasted to surge to $2.45 billion by 2029 with a compound annual growth rate (CAGR) of 10.2%. Factors contributing to this predicted growth during the forecast period include the growing significance of personalized medicine, a rise in diagnostic tests, enhanced focus on tailored cancer therapy, higher healthcare spending, and growth in cancer prevalence and awareness. The forecast period is also expected to witness major trends such as improvements in diagnostic technologies, the emergence of next-generation sequencing (NGS), the application of artificial intelligence (AI), advancements in liquid biopsy technologies, the production of point-of-care companion diagnostic devices, and breakthroughs in testing technologies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15528&type=smp
What Underlying Factors Are Supporting The Cancer Immunotherapy Drug Discovery Outsourcing Market Growth?
The escalating costs linked to research and development are projected to stimulate the expansion of the cancer immunotherapy drug discovery outsourcing market. These high expenses are mainly attributed to the requirement for specialist expertise, high-priced equipment, and the inherent dangers associated with innovation. Subcontracting drug discovery duties allows the advantage of economies of scale offered by contract research organizations (CROs), permitting smaller biotech firms and startups to maximize their R&D budgets and distribute resources more effectively, boosting cost-efficiency. For example, as per the information from the European Federation of Pharmaceutical Industries and Associations (EFPIA), a trade association that represents the pharmaceutical industry in Europe, the total pharmaceutical research and development expenditure in Europe measured up to $49,500 million (€44,500 million) in 2022, showing an approximate rise of 6.45% from $46,500 million (€42,533 million) in 2021. Consequently, the exorbitant price of in-house research and development is fueling the emergence of the cancer immunotherapy drug discovery outsourcing market.
Which Sub-Segments Are Driving Growth Within The Cancer Immunotherapy Drug Discovery Outsourcing Market?
The cancer immunotherapy drug discovery outsourcing market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies And Cancer Vaccines, Other Drug Types
2) By Service Type: Target Identification And Validation, Lead Screening And Characterization, Cell-Based Assays
3) By Therapeutic Area: Lung Cancer, Breast Cancer, Melanoma, Other Therapeutic Areas
Subsegments:
1) By Monoclonal Antibodies: Checkpoint Inhibitors, Therapeutic Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
2) By Immunomodulators: Cytokines, Immune Checkpoint Modulators, Toll-Like Receptor Agonists, Immune Adjuvants
3) By Oncolytic Viral Therapies And Cancer Vaccines: Oncolytic Virus-Based Therapies, Cancer Vaccines, Viral Vectors For Immunotherapy
4) By Other Drug Types: Adoptive Cell Therapy, Immune Cell Modulators, Small Molecule Immune Modulators, Gene Editing And Immunotherapy
What Future-Focused Trends Are Anticipated In The Cancer Immunotherapy Drug Discovery Outsourcing Market?
Key players in the sector of cancer immunotherapy drug discovery outsourcing are leveraging strategic partnerships to advance their production of cancer drugs and gain a competitive advantage in the market. A strategic partnership typically involves the pooling of resources, knowledge, and efforts by two or more entities to achieve shared goals or objectives. To highlight an example, Ono Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, and Bristol-Myers Squibb, a biopharmaceutical firm from the US, have entered an outsourcing agreement in February 2022 with the Japan-based Prime Research Institute for Medical Research, Inc.. This is for a joint clinical research project targeting gastric cancer patients who are treated with Opdivo (nivolumab) and chemotherapy. This collaboration is hosted by the industry and operates a large-scale study across several institutions by utilising PRiME-R’s CyberOncology data input support system. This allows for standardization, organization, management, and integration of data gathered from routine cancer clinical practice. The clinical research that leverages CyberOncology evaluates the use of Opdivo in conjunction with chemotherapy in patients experiencing their first instance of advanced or recurrent gastric cancer. This study involves around 30 medical institutions throughout the country and focuses on improving data input, enhancing data accuracy, and facilitating quicker analysis.
Which Organizations Are At The Forefront Of The Cancer Immunotherapy Drug Discovery Outsourcing Market?
Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc., ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Jubilant Biosys, Oncodesign Services, Icagen Inc., Reaction Biology Corporation, ChemBridge Corporation
Access The Complete Report Here:
Which Region Dominates The Cancer Immunotherapy Drug Discovery Outsourcing Market Today?
North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=15528&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
